Sitagliptin
- Generic Name
- Sitagliptin
- Brand Names
- Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15F6N5O
- CAS Number
- 486460-32-6
- Unique Ingredient Identifier
- QFP0P1DV7Z
- Background
Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on Oct...
- Indication
Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.
It is also used in combination with metformin or ertugliflozin.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2020-09-11
- Target Recruit Count
- 90
- Registration Number
- NCT04298684
- Locations
- 🇷🇪
CHU de la Réunion, Saint-Pierre, Réunion
🇫🇷CHU Limoges, Limoges, France
🇬🇵University Hospital Center of Guadeloupe, Pointe-à-Pitre, Guadeloupe
Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS Patients
- Conditions
- Interventions
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT04268563
- Locations
- 🇮🇷
Mahdiyeh educational hospital, Tehran, Iran, Islamic Republic of
Study of Real-world Evidence With SGLT2i (Dapagliflozin) and DPP4i (Sitagliptin) in Type 2 Diabetes Patients in Spain
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2019-11-04
- Target Recruit Count
- 1080
- Registration Number
- NCT04149067
- Locations
- 🇪🇸
Cristóbal Morales Portillo, Sevilla, Andalucía, Spain
A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1441
- Registration Number
- NCT04017832
- Locations
- 🇩🇿
Maison des diabétiques El Harrach, Algiers, Algeria
🇩🇿Department of internal medicine hospital (CHU) of BIRTRARIA, Algiers, Algeria
🇧🇷Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda., Porto Alegre, Rio Grande Do Sul, Brazil
Replication of the TECOS Diabetes Trial in Healthcare Claims
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 349476
- Registration Number
- NCT03936062
- Locations
- 🇺🇸
Brigham & Women's Hospital, Boston, Massachusetts, United States
Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- University of Copenhagen
- Target Recruit Count
- 12
- Registration Number
- NCT03893526
- Locations
- 🇩🇰
Hvidovre Hospital, Hvidovre, RegionH, Denmark
Drug Interaction Study Between Dorzagliatin and Sitagliptin
- First Posted Date
- 2019-01-02
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Hua Medicine Limited
- Target Recruit Count
- 15
- Registration Number
- NCT03790839
- Locations
- 🇺🇸
Frontage Clinical Services Inc., Hackensack, New Jersey, United States
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1
- Conditions
- Interventions
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT03738878
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Glucagon-like Peptide-1 Levels, Insulin Resistance and Insulin Sensitivity Index in Type 2 Diabetes Mellitus
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- National University of Malaysia
- Target Recruit Count
- 174
- Registration Number
- NCT03659461
- Locations
- 🇲🇾
Hospital Sultan Ismail, Johor Bahru, Johor, Malaysia
A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM
- Conditions
- Interventions
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Dong-A ST Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT03646721
- Locations
- 🇺🇸
Clinical Site, Chula Vista, California, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸High Point Clinical Trials Center, High Point, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.